FIG. 6.

(A) Data from one representative experiment showing production of the active form of caspase-3 (upper row of histograms) or the induction of apoptosis (lower row of histograms) in IAV-exposed CD3⁺ cells (solid histograms). The sham-exposed caspase-3 level or percent apoptosis is shown as the gray line in the far left histogram of each row. The effect of treatment of IAV-exposed cells with recombinant soluble human Fas, anti-FasL antibody, the general caspase inhibitor Z-VAD-FMK, or the caspase-3 inhibitor AC-DEVD-CHO are shown. Treatment of sham-exposed CD3⁺ cells with recombinant soluble human Fas, anti-FasL antibody, the general caspase inhibitor Z-VAD-FMK, or the caspase-3 inhibitor AC-DEVD-CHO produced levels of caspase-3 less than 1.3% and levels of apoptosis less than 1%. For each sample, data from 10,000 CD3⁺ cells were collected. (B) Active caspase-3 production in CD3⁺ sham-exposed (open bars; left graph) and virus-exposed (solid bars; right graph) lymphocytes after treatment with anti-FasL antibody, recombinant soluble human Fas, the general caspase inhibitor Z-VAD-FMK, or the caspase-3 inhibitor AC-DEVD-CHO. Results represent the mean percentage of apoptotic cells ± SD from five experiments, showing the effect of the above treatments. For each sample, data from 10,000 CD3⁺ cells were collected. (C) Apoptosis of CD3⁺ sham-exposed (open bars; left graph) and virus-exposed (solid bars; right graph) lymphocytes after treatment with anti-FasL antibody, recombinant soluble human Fas, the general caspase inhibitor Z-VAD-FMK, or the caspase-3 inhibitor AC-DEVD-CHO. Results represent the mean percentage of apoptotic cells ± SD from five experiments, showing the effect of the above treatments. For each sample, data from 10,000 CD3⁺ cells were collected.